ClinicalTrials.gg
Not yet recruitingNCT07044349Updated Jun 30, 2025

Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2 interventional study of Utidelone capsule 75mg/m2/d QD and Utidelone capsule 40mg/m2/d BID in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-30.

Sponsored by Beijing Biostar Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is an open, multicenter, phase II clinical study enrolling patients with platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to evaluate the safety and efficacy of Utidelone Capsules. Approximately 72 patients will be included in this study.

Read the detailed description

This study will be two cohorts:

Cohort 1: 30 participants are planned to be enrolled. The administration regimen is Utidelone Capsules at 75 mg/m2/d once a day. Fasting (fasting for 2 hours before administration and 1 hour after administration)is required from the 1st to the 5th day of each 21-day cycle.

Cohort 2: 6 to 12 participants are planned to be enrolled during the safety run-in part, and 30 participants are planned to be enrolled during the expansion part. The administration regimen is the twice daily (BID) administration of Utidelone capsules. The dosage of expansion part will be determined according to the safety run-in part. Fasting (fasting for 2 hours before administration and 1 hour after administration)is required from the 1st to the 5th day of each 21-day cycle.

The safety run-in part use a dose-escalation design. The initial dose was 40 mg/m2 of utidelone capsules BID. The escalation group was set at 50 mg/m2 BID or the de-escalation group at 35 mg/m2 BID. 6 participants will be enrolled in each dose group to evaluate dose-limiting toxicity (DLT).

After the completion of DLT observation during the safety run-in part, one administration regimen will be determined for the dose expansion period.

02

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Keywords

  • UTD2
  • Utidelone Capsule
03

In context

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

This study's planned enrollment of 72 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Beijing Biostar Pharmaceuticals Co., Ltd. is the lead sponsor of 14 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who voluntarily sign the form, are willing and able to comply with the scheduled visits, study treatment plan, laboratory tests, and other study procedures.
  2. Female participants aged ≥ 18 years when signing the informed consent form.
  3. confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  4. Participants with at least one as defined per v1.1.
  5. Participants must meet the criteria for platinum-resistant recurrence, which is defined as disease progression during platinum-based therapy or disease progression or recurrence within 6 months after the last platinum-based therapy. Note: Participants must have radiographically confirmed disease progression during or after the most recent . Biochemical progression is not considered disease progression in this study.
  6. Participants must meet the requirements of failure or intolerance to the existing standard of treatment or no standard of treatment. Prior use of at least 1 but ≤ 3 lines of systemic antitumor treatment ( and adjuvant treatment are not considered prior systemic treatment, unless disease progression occurred during treatment or within 6 months after the last dose of treatment). Maintenance therapy (e.g., bevacizumab, poly-ADP ribose polymerase [PARP] inhibitors, hormonal therapy) is considered part of the prior line of treatment. Treatment changes due to toxicity without progression will be considered part of the prior line of treatment (i.e., not counted separately).
  7. (ECOG) performance status of 0 or 1.
  8. Hematology test within 7 days prior to enrollment (based on the laboratory normal range at each site), and no use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) or blood products /erythropoietin (EPO) within 14 days prior to the laboratory test during the screening period.

    (ANC) ≥ 1.5 × 109/L; count (PLT) ≥ 100 × 109/L; ≥ 9.0 g/dL.

  9. Blood chemistry test within 7 days prior to enrollment (based on the laboratory normal range at each site); Total (TBIL) ≤ 1.5 × (ULN); ≤ 3 × ULN (≤ 5 × ULN for participants with liver ); AST ≤ 3 × ULN (≤ 5 × ULN for participants with liver metastasis); (Ccr) ≥ 60 mL/min (calculated by Cockcroft-Gault formula).
  10. ≥ 12 weeks.
  11. Female participants of must agree to use highly effective methods and not to donate eggs during the study and for 8 weeks after the last dose of study treatment. Female patients of childbearing potential must have a negative blood or urine pregnancy test result at screening and be willing to undergo additional pregnancy tests as needed throughout the study. See Appendix 1 for details.

Exclusion criteria

Exclusion Criteria:

  1. The best overall response during the platinum-based treatment is disease progression, or disease recurrence or progression within 3 months after the end of the platinum-based treatment.
  2. History of other within 5 years prior to enrollment, excluding cured skin basal cell carcinoma, cervical carcinoma in situ, or papillary thyroid carcinoma.
  3. Anti-tumor therapy, including chemotherapy, radiotherapy, target therapy, immunotherapy, etc. within 4 weeks prior to the first dose of the drug, except for the following items;

    1. Received nitrosourea or mitomycin C within 6 weeks prior to the first dose of the investigational drug;
    2. Oral fluorouracil, small molecule targeted drugs, or endocrine therapy within 2 weeks or within 5 half-lives of the drug prior to the first dose of the investigational drug, whichever is shorter;
    3. Use of traditional Chinese medicine with anti-tumor indications or endocrine therapy within 2 weeks prior to the first dose of the investigational drug.
  4. Participants who have undergone major surgery (craniotomy, thoracotomy, or laparotomy, or as defined by the investigator) or have experienced significant trauma within 4 weeks prior to the first dose of the investigational product, or those who require elective surgery during the study.
  5. Participants with adverse reactions due to previous antitumor therapy that have not recovered to Grade ≤1 (based on 5.0), except toxicities without safety risks as judged by the investigator, such as alopecia.
  6. Participants with gastrointestinal perforation, gastrointestinal fistula, or intra-abdominal abscess, or patients with gastrointestinal hemorrhage, gastrointestinal obstruction (including paralytic ileus), or imaging/clinical symptoms suggestive of bowel obstruction within 3 months prior to the first use of the investigational product;
  7. Participants who are unable to take oral medications, or with other factors that interfere with the oral administration and absorption of the drug, or those who require total parenteral nutrition.
  8. Participants who need concomitant use of strong inhibitors or inducers, or medications that prolong the , within 14 days prior to the first use of the investigational product or during the study.
  9. Participants with symptomatic or uncontrolled central nervous system (CNS) or meningeal metastases, i.e., patients with disease progression confirmed by examination within 2 months after radiotherapy or other local treatments, or patients who are judged by the investigator to be unsuitable for enrollment.
  10. Uncontrolled bone metastases, i.e., patients who have experienced fracture or have the risk of fracture in recent days, patients who need surgery or localized radiotherapy in recent days, or those with other critical conditions as determined by the investigator.
  11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once per month or more frequently).
  12. History of severe cardiovascular and cerebrovascular diseases, including but not limited to:

    Patients with acute myocardial infarction, severe/uncontrolled angina, or coronary artery bypass surgery within 6 months prior to the first dose of the investigational product; congestive heart failure with a (NYHA) classification ≥ 2; (LVEF) \< 50%; Fridericia corrected QT interval > 470 ms (average of three measurements); or a history of myocarditis (including patients with a past history of myocarditis that recovered after treatment) or other Grade ≥ 3 cardiovascular events.

    Stroke and/or within 6 months prior to the first dose of the investigational product; Uncontrolled hypertension despite standard treatment; Other heart diseases at high risk, as judged by the investigator.

  13. Participants with uncontrolled diabetes mellitus.
  14. Participants with active and/or , i.e., HBsAg positive and HBV DNA positive; anti-HCV positive and HCV RNA positive; positive for (HIV) antibody; positive for treponema pallidum specific antibody.
  15. Participants who had active infection prior to screening and initial use of the investigational drug and required systemic anti-infective therapy.
  16. Pregnant or breastfeeding women, or women who plan to become pregnant during the study.
  17. Participants with mental disorder or poor compliance.
  18. Participants with prior use of utidelone.
  19. Participants with known to the investigational product or any of the .
  20. Participants who simultaneously participate in another interventional clinical trial or use other investigational therapies.
  21. Participants who, in the opinion of the investigator, are not suitable to participate in this study due to history of severe systemic diseases or other reasons.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Drug: Utidelone capsule 75mg/m2/d QD

  • Experimental
    Cohort 2 initial group

    Drug: Utidelone capsule 40mg/m2/d BID

  • Experimental
    Cohort 2 escalation group

    Drug: Utidelone capsule 50mg/m2/d BID

  • Experimental
    Cohort 2 de-escalation group

    Drug: Utidelone capsule 35mg/m2/d BID

Interventions

  • DrugUtidelone capsule 75mg/m2/d QD

    Drug page: Desoxyepothilone B

    75mg/m2/d, QD, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

  • DrugUtidelone capsule 40mg/m2/d BID

    Drug page: Desoxyepothilone B

    40mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

  • DrugUtidelone capsule 50mg/m2/d BID

    Drug page: Desoxyepothilone B

    50mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

  • DrugUtidelone capsule 35mg/m2/d BID

    Drug page: Desoxyepothilone B

    35mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) and the maximum tolerated dose of the BID administration regimen

    Time frame: Until 21 days after the first dose of treatment

  2. The incidence of adverse events (AE)/serious adverse events (SAE)

    Time frame: Until 28 days after the last dose of treatment

Secondary outcomes

  1. Objective response rate (ORR)

    based on RECIST v1.1

    Time frame: 18 months

  2. Disease control rate (DCR)

    Time frame: 18 months

  3. Progression-free survival (PFS)

    Time frame: 18 months

  4. Maximum (or peak) serum concentration-Cmax

    Time frame: 18 months

  5. Time to peak drug concentration-Tmax

    Time frame: 18 months

  6. The area under the concentration-time curve from dosing (time 0) to time t-AUC0-t

    Time frame: 18 months

  7. The time required for plasma concentration of a drug to decrease by 50%-t1/2

    Time frame: 18 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Mar 2027, 18 months later.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 18 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jun 30, 2025
StartEst.
Sep 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jun 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07044349
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Jun 30, 2025
Start date
Sep 2025 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 30, 2025

Study contacts

Rongguo Qiu
Contact
Rqiu2001@yahoo.com
010-56315388
Xiaohua Wu
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desoxyepothilone B

Start the discussion